Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
Cell-type-specific innate immune response to oncolytic Newcastle disease virus
Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation
Recent clinical experience with oncolytic viruses
Bugs and drugs: oncolytic virotherapy in combination with chemotherapy
Immunotherapies for non-small-cell lung cancer and mesothelioma
Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study
Old and new facts about hyperthermia-induced modulations of the immune system
Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells.
Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.
WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.
The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.
Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
CD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma.
Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients.
Dendritic/tumor fusion cells as cancer vaccines